Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Novel Patented Src Kinase Inhibitor

Author(s): Xiao-Ling Lu, Xiao-Yu Liu, Xin Cao and Bing-Hua Jiao

Volume 19, Issue 12, 2012

Page: [1821 - 1829] Pages: 9

DOI: 10.2174/092986712800099802

Price: $65

Abstract

Src family of protein tyrosine kinases (SFKs) plays key roles in the regulation of signal transductions in cellular processes. However, hyper-activated SFKs lead to uncontrolled cell proliferation and cancers. Src-targeted compounds were developed to block the cell proliferation signal transductions for cancer therapy. Src kinase domain inhibitors were designed, synthesized and evaluated as anticancer agents, while the patents applied at the same time. Great progress has been made in the Src kinase inhibitor area. Herein, some predominant patents about Src kinase inhibitors of the recent years are reviewed.

Keywords: Anticancer, AZD-0530, BMS-354825, carcinogenesis, inhibitor, kinase domain, SKI-606, Src kinase


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy